Odronextamab

– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy – – This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCL – – Data were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentation – SOUTH SAN FRANCISCO, CA, USA I June 15, 2024 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi ® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan ® (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.Data were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at the European Hematology Association (EHA) 2024 Congress as a late-breaking oral presentation. “The results from STARGLO are the first to show the potential of a CD20xCD3 bispecific antibody to make a difference in second or later-line DLBCL in people who are ineligible for transplant and have limited options,” said Jeremy Abramson, M.D., director, Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, and principal investigator of the STARGLO study. “Glofitamab in combination with GemOx showed clinically significant improvement in overall survival, as well as key secondary endpoints, and the benefits were reinforced with an additional 11 months of follow-up.” The primary analysis (median follow-up of 11.3 months) confirmed that the study met its primary endpoint of overall survival (OS), demonstrating that patients treated with Columvi plus GemOx lived significantly longer, with a 41% reduction in the risk of death (hazard ratio [HR]=0.59, 95% CI: 0.40-0.89, p=0.011) versus R-GemOx. Median OS was not reached with the Columvi regimen versus nine months for R-GemOx.Safety of the combination appeared consistent with the known safety profiles of the individual medicines. Pre-specified exploratory subgroup analyses showed comparable results, including consistency across the clinically relevant stratification factors of line of therapy (second-line versus third-line+) and outcome of last therapy (relapsed versus refractory). Regional inconsistencies were observed, however interpretation is limited given the exploratory nature of these analyses and small subgroups with wide confidence intervals. “This marks a first step in advancing Columvi combinations in earlier settings to address the urgent need for the 40% of people who will relapse or have refractory disease and who have limited options,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “Moreover, patients do not have to wait to start treatment with Columvi. This could be particularly important for patients with highly aggressive disease who are at risk of rapid disease progression.” The Columvi combination also met its key secondary endpoints, with a 63% reduction in risk of disease worsening or death (progression-free survival, PFS) compared to R-GemOx (HR=0.37; 95% CI: 0.25–0.55, p<0.0001). A follow-up analysis was conducted after all patients had completed therapy (median follow-up of 20.7 months), which showed continued benefit in both primary and secondary endpoints. Median OS for people treated with the Columvi combination was 25.5 months, nearly double what was seen for people treated with R-GemOx at 12.9 months, and more than twice as many patients experienced a complete response (58.5% versus 25.3%, respectively). Adverse event (AE) rates were higher with the Columvi combination versus R-GemOx, noting higher median number of cycles received with Columvi combination (11 versus 4). One of the most common AEs was cytokine release syndrome, which was generally low grade (Any Grade: 44.2%, Grade 1: 31.4%, Grade 2: 10.5%, Grade 3: 2.3%) and occurred primarily in Cycle 1. Columvi is the first CD20xCD3 bispecific antibody to demonstrate a survival benefit in DLBCL in a randomized Phase III trial, demonstrating the potential of this type of therapeutic combination to improve survival outcomes in earlier lines of treatment. The standard second-line therapy for R/R DLBCL patients has historically been high-dose chemotherapy followed by stem-cell transplant, however, not everyone with R/R DLBCL is a candidate due to age or coexisting medical conditions. Newer therapies are also becoming available, but barriers remain for many, and alternative treatment options are needed for these patients. Columvi is given as a fixed-duration treatment, offering people with R/R DLBCL a treatment end date and the possibility of a treatment-free period, unlike continuous treatments. Results from the STARGLO study will be submitted to global health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency. Columvi is also being investigated in other aggressive, hard-to-treat lymphomas and was recently granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior therapies based on results from the Phase I/II NP30179 study. About the STARGLO Study The STARGLO study [GO41944; NCT04408638 ] is a Phase III, multicenter, open-label, randomized study evaluating the efficacy and safety of Columvi ® (glofitamab-gxbm) in combination with gemcitabine plus oxaliplatin (GemOx) versus Rituxan ® (rituximab) in combination with GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy. Outcome measures include overall survival (primary endpoint), progression-free survival, complete response rate, objective response rate, duration of objective response (secondary endpoints), and safety and tolerability. STARGLO is intended as a confirmatory study to convert Columvi’s accelerated approval in the U.S. and conditional marketing authorization in the EU to full approvals for people with R/R DLBCL after two or more lines of systemic therapy based on the pivotal Phase I/II NP30179 study. About Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma (NHL) in the U.S. While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes. DLBCL not otherwise specified is the most common category of large B-cell lymphoma (LBCL) and accounts for about 80% or more of cases. It applies to cases that do not fall into any specific disease subgroups of LBCL. About Columvi ® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. A clinical development program for Columvi is ongoing, investigating the molecule as a monotherapy and in combination with other medicines for the treatment of people with B-cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma and other blood cancers. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. Please see Important Safety Information, including Serious Side Effects , as well as the Columvi full Prescribing Information and Medication Guide or visit https://www.Columvi.com . About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology . About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . SOURCE: Genentech

Roche presented updated, longer-term overall survival (OS) data from the Phase III STARGLO trial reinforcing what researchers said was a "statistically significant and clinically meaningful" survival benefit for the CD20xCD3 bispecific antibody Columvi (glofitamab) in earlier-line relapsed/refractory diffuse large B-cell lymphoma (DLBCL).The results, unveiled Friday at the European Hematology Association (EHA) annual meeting, shed more light on top-line findings first reported in April showing Columvi plus chemotherapy hit the trial's primary endpoint of improved OS versus the Rituxan/MabThera (rituximab)-chemo combo. They also bolster Roche's case as it looks to broaden the drug's label into earlier-line settings.Battle of bispecificsRegulators last year in the US, Europe and Canada granted early approval to Columvi for third-line DLBCL patients based on response-rate data from a Phase I/II trial. The STARGLO readout will be key as Roche looks to set Columvi apart from rivals including AbbVie/Genmab's Epkinly (epcoritamab), a drug in the same class that is also authorised in third-line DLBCL.Regeneron is keen for its CD20xCD3 bispecific odronextamab to join them on the market, but the FDA wants the company to make more headway with confirmatory studies. The agency rejected filings for odronextamab in third-line relapsed/refractory follicular lymphoma and DLBCL earlier this year. For more, see Spotlight On: Regeneron’s odronextamab forces FDA to draw line in sand on accelerated approvals.The STARGLO study enrolled 274 people with relapsed or refractory DLBCL who received at least one prior line of therapy and are not candidates for autologous stem cell transplant. Participants were randomised to receive Columvi or Rituxan/MabThera, both in combination with gemcitabine plus oxaliplatin. Roughly two-thirds had been treated with just one prior therapy, while the remaining had received at least two.Triumph on key survival measuresAs of the primary analysis cutoff date of March 2023, Columvi was associated with an OS benefit of 41% compared to the comparator arm. It also showed a significant improvement in progression-free survival (PFS) of 63%, with complete response (CR) rates of 50.3% versus 22% for the Columvi and Rituxan/MabThera arms, respectively.Once all patients had completed therapy, the follow-up analysis with a cutoff of February 16 this year, showed that the Columvi regimen continued to demonstrate superior median OS of 25.5 months versus 12.9 months for the comparator arm. That translated to an OS benefit of 38% in favour of Roche's CD20xCD3 bispecific. Columvi also bested Rituxan/MabThera on PFS with a benefit of 60% (13.8 vs 3.6 months), as well as CR rate (58.5% vs 25.3%).Researchers noted that Columvi "is the first CD20xCD3 bispecific antibody to demonstrate survival benefit in DLBCL in a randomised Phase III trial."However, the Columvi combo resulted in more adverse events (AEs) compared to the Rituxan regimen. Nearly 70% of Columvi patients experienced Grade 3 or 4 side effects versus 36% on Rituxan. In addition, around 8% of Columvi patients died during the study, compared to 4.5% with Rituxan – an imbalance that was driven by more COVID-19-related AEs. Adjusting for greater exposure, researchers noted that AE rates were similar between the arms.